Free Trial
NASDAQ:IFRX

InflaRx (IFRX) Stock Price, News & Analysis

InflaRx logo
$1.55
-0.02 (-1.27%)
(As of 10/31/2024 ET)

About InflaRx Stock (NASDAQ:IFRX)

Key Stats

Today's Range
$1.49
$1.60
50-Day Range
$1.42
$1.66
52-Week Range
$1.14
$2.10
Volume
88,059 shs
Average Volume
156,252 shs
Market Capitalization
$91.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50
Consensus Rating
Strong Buy

Company Overview

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

InflaRx Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
71st Percentile Overall Score

IFRX MarketRank™: 

InflaRx scored higher than 71% of companies evaluated by MarketBeat, and ranked 318th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    InflaRx has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    InflaRx has only been the subject of 1 research reports in the past 90 days.

  • Read more about InflaRx's stock forecast and price target.
  • Earnings Growth

    Earnings for InflaRx are expected to decrease in the coming year, from ($0.98) to ($1.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InflaRx is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InflaRx is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    InflaRx has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about InflaRx's valuation and earnings.
  • Percentage of Shares Shorted

    0.41% of the outstanding shares of InflaRx have been sold short.
  • Short Interest Ratio / Days to Cover

    InflaRx has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InflaRx has recently decreased by 8.06%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    InflaRx does not currently pay a dividend.

  • Dividend Growth

    InflaRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.41% of the outstanding shares of InflaRx have been sold short.
  • Short Interest Ratio / Days to Cover

    InflaRx has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InflaRx has recently decreased by 8.06%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    InflaRx has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for InflaRx this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for IFRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InflaRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about InflaRx's insider trading history.
Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

IFRX Stock News Headlines

Buy Rating on InflaRx as Gohibic Shows Promise and Financials Strengthen
We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
3 Penny Stocks To Buy With Just $750
IFRX Sep 2024 2.500 call (IFRX240920C00002500)
See More Headlines

IFRX Stock Analysis - Frequently Asked Questions

InflaRx's stock was trading at $1.63 at the start of the year. Since then, IFRX shares have decreased by 4.9% and is now trading at $1.55.
View the best growth stocks for 2024 here
.

InflaRx (NASDAQ:IFRX) issued its earnings results on Thursday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.04 million. InflaRx had a negative trailing twelve-month return on equity of 47.03% and a negative net margin of 44,046.09%.

InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include G1 Therapeutics (GTHX), Xeris Biopharma (XERS), Bristol-Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA).

Company Calendar

Last Earnings
8/08/2024
Today
10/31/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IFRX
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.50
High Stock Price Target
$19.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+759.9%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-46,180,000.00
Net Margins
-44,046.09%
Pretax Margin
-44,115.65%

Debt

Sales & Book Value

Annual Sales
$105,483.00
Book Value
$1.89 per share

Miscellaneous

Free Float
49,285,000
Market Cap
$92.45 million
Optionable
Optionable
Beta
1.57
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:IFRX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners